Rheumatic Heart Disease School Project
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01550068|
Recruitment Status : Recruiting
First Posted : March 9, 2012
Last Update Posted : September 21, 2017
Acute rheumatic Fever (ARF) results from an autoimmune response due to molecular mimicry between the M-protein on the group A β-hemolytic streptococci (GABHS) cell membrane and cardiac myosin, and may lead through recurrent or sustained inflammation to Rheumatic Heart Disease (RHD). RHD remains a major contributor to morbidity and premature death in the working age population in Nepal. Secondary prevention with regular oral or intravenous administration of penicillin continued until early adulthood is recommended to prevent the progression of the development of endocarditis and subsequent valvular dysfunction.
Screening for rheumatic heart disease using echocardiography has the potential to detect rheumatic valvular lesions at an earlier, clinically silent stage, as compared to clinical examination alone and might have a beneficial impact on long-term outcome of children with RHD. Schoolchildren aged 5-15 years from several public and private schools from rural and urban areas in Southeastern Nepal will be screened for RHD using portable echocardiography.
Three main inter-related objectives will be pursued in three phases of the study: In a first phase using a cross sectional approach, the prevalence of clinical and subclinical RHD will be investigated among a representative sample of schoolchildren from public and private schools in urban and rural areas. In a second phase, using a cohort study approach among those children diagnosed at different stages of RHD, clinical outcomes with regular medical surveillance will be assessed (a), and clinical and social risk factors associated with prognosis of the disease after receiving medical care at various stages of disease at diagnosis will be determined (b). A third phase will integrate the prevalence rates from phase 1 and the clinical outcomes from phase 2 in a mathematical model to assess the impact of screening and RHD treatment on health resource utilization.
|Condition or disease|
|Rheumatic Heart Disease|
Show Detailed Description
|Study Type :||Observational|
|Estimated Enrollment :||5476 participants|
|Observational Model:||Ecologic or Community|
|Official Title:||A Population-Based Study of Prevalence of Rheumatic Heart Disease and Cardiovascular Outcomes Among Schoolchildren in Nepal|
|Study Start Date :||December 2012|
|Estimated Primary Completion Date :||March 2019|
|Estimated Study Completion Date :||March 2019|
Schoolchildren aged 5-15 years from public and private schools in urban and rural area in Southeast Nepal
- Prevalence of Rheumatic Heart Disease [ Time Frame: 12 Months Screening Period ]
- composite of all-cause mortality, stroke, endocarditis, hospitalization for congestive heart failure, valvular surgery, mitral balloon valvuloplasty, and recurrence of rheumatic fever [ Time Frame: 5 years ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01550068
|Contact: Thomas Pilgrim, MD||+41 31 632 21 email@example.com|
|Contact: Nikesh R Shrestha, MD, FESC||+977 985 204 firstname.lastname@example.org|
|Department of Internal Medicine and Cardiology||Recruiting|
|B.P. Koirala Institute of Health Sciences (BPKIHS), Dharan, Nepal, 765000|
|Contact: Nikesh R Shrestha, MD, FESC +977 985 204 5083 email@example.com|
|Principal Investigator: Nikesh R Shrestha, MD, FESC|
|Principal Investigator:||Thomas Pilgrim, MD||Department of Cardiology, Bern University Hospital, Switzerland|
|Principal Investigator:||Nikesh R Shrestha, MD, FESC||Department of Internal Medicine and Cardiology, B.P. Koirala Institute of Health Sciences (BPKIHS)|